Skip to main content

Wave Life Sciences Ltd. (WVE) Stock Analysis

Recovery setup

SellModerate Confidence

Healthcare · Biotechnology

Sell if holding. Engine safety override at $7.07: Quality below floor (1.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.1/10. Specifically: Below-average business quality; Rich valuation; Below long-term trend.

Wave Life Sciences is a clinical-stage RNA medicines company with lead programs WVE-007 (obesity, GalNAc siRNA), WVE-006 (AATD, RNA editing AIMer), WVE-008 (PNPLA3 I148M liver disease, RNA editing AIMer), plus clinical programs for DMD and Huntington disease. The company had an... Read more

$7.07+7.4% A.UpsideScore 4.1/10#146 of 158 Biotechnology
Stop $6.63Target $7.59(resistance)A.R:R 0.0:1
Analyst target$23.13+227.1%16 analysts
$7.59our TP
$7.07price
$23.13mean
$52

Sell if holding. Engine safety override at $7.07: Quality below floor (1.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.1/10. Specifically: Below-average business quality; Rich valuation; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 46. Score 4.1/10, moderate confidence.

Passes 5/8 gates (positive momentum, no SEC red flags, news boost analyst 0.40, earnings proximity 89d clear, semi cycle peak clear). Fails on clean insider activity. Suitability: aggressive.

Val0.0Qual1.9Grw5.0Mom5.2Sent8.2Ins6.2Peer4.3Tech4.9Risk4.64.1OVERALL

Thesis

Rewards
Recent Analyst detected in news
Risks
DATA_ISSUE: analyst_target_implausible (raw $23.12 vs price $7.07 — ratio 3.3×). Rejected, falling back to technical TP.
Quality below floor (1.9 < 4.0)

Key Metrics

P/E (TTM)—
P/E (Fwd)-6.3
Mkt Cap$1.4B
EV/EBITDA-4.3
Profit Mgn-255.7%
ROE-53.1%
Rev Growth316.9%
Beta-1.32
DividendNone
Rating analysts20

Quality Signals

Piotroski F3/9

Options Flow

P/C0.18bullish
IV69%elevated
Max Pain$4-43.4% vs spot

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

2 floor-breakers

Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static

Ps
0.0
Expensive valuation
Low model confidence on this dimension (20%).

Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static

Roe
0.0
Roa
0.0
Operating Margin
0.0
Fcf Quality
0.0
Piotroski F
3.3
Current Ratio
5.0
Moat
5.0
Cash-burning: FCF -175% of revenueNo competitive moatWeak Piotroski F-Score: 3/9Quality concerns
GatesINSIDER 3.97%=EXTREMEMomentum 5.2<5.5 (soft — BUY_NOW allowed but watch)A.R:R UPSIDE_EXHAUSTED (upside=0.0%)Momentum 5.2>=4.5No SEC red flagsNEWS BOOST ANALYST 0.40EARNINGS PROXIMITY 89d clearSEMI CYCLE PEAK CLEARRecoverySuitability: Aggressive
RSI
46 · Neutral
↓ 20D MA↓ 50D MA↓ 200D MADEATH CROSSSupport $6.83Resistance $7.74

Price Targets

$7
$8
A.Upside+7.4%
A.R:R0.0:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! DATA_ISSUE: analyst_target_implausible (raw $23.12 vs price $7.07 — ratio 3.3×). Rejected, falling back to technical TP.
! Quality below floor (1.9 < 4.0)
! Insider activity: 3.97%=extreme

Earnings

B
M
M
M
1/4 beats
Next Earnings2026-07-29 (89d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is WVE stock a buy right now?

Sell if holding. Engine safety override at $7.07: Quality below floor (1.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.1/10. Specifically: Below-average business quality; Rich valuation; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 46. Prior stop was $6.63. Score 4.1/10, moderate confidence.

What is the WVE stock price target?

Take-profit target: $7.59 (+7.4% upside). Prior stop was $6.63. Stop-loss: $6.63.

What are the risks of investing in WVE?

DATA_ISSUE: analyst_target_implausible (raw $23.12 vs price $7.07 — ratio 3.3×). Rejected, falling back to technical TP.; Quality below floor (1.9 < 4.0).

Is WVE overvalued or undervalued?

Wave Life Sciences Ltd. trades at a P/E of N/A (forward -6.3). TrendMatrix value score: 0.0/10. Verdict: Sell.

What do analysts say about WVE?

20 analysts cover WVE with a consensus score of 4.3/5. Average price target: $23.

What does Wave Life Sciences Ltd. do?Wave Life Sciences is a clinical-stage RNA medicines company with lead programs WVE-007 (obesity, GalNAc siRNA),...

Wave Life Sciences is a clinical-stage RNA medicines company with lead programs WVE-007 (obesity, GalNAc siRNA), WVE-006 (AATD, RNA editing AIMer), WVE-008 (PNPLA3 I148M liver disease, RNA editing AIMer), plus clinical programs for DMD and Huntington disease. The company had an accumulated deficit of $1,326.2M as of December 31, 2025.

Related stocks: HRMY (Harmony Biosciences Holdings, I) · AUPH (Aurinia Pharmaceuticals Inc) · CPRX (Catalyst Pharmaceuticals, Inc.) · NVAX (Novavax, Inc.) · INVA (Innoviva, Inc.)